Literature DB >> 8132737

1,1'-Ethylidenebis(tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant.

K A Yamaoka1, N Miyasaka, G Inuo, I Saito, J P Kolb, K Fujita, S Kashiwazaki.   

Abstract

This study was designed to clarify the important association between eosinophilia-myalgia syndrome (EMS) and the L-tryptophan contaminant, "Peak E." To determine the functional activation of eosinophils induced by Peak E, eosinophil cationic protein (ECP) release was examined. Peak E augumented the release of ECP from peripheral blood normodense eosinophils by degranulation. Proliferative analysis using the human eosinophilic leukemia cell line EoL-3 showed prominent cellular replication in the presence of Peak E. Moreover, Peak E upregulated interleukin 5 (IL-5) receptor levels on normodense eosinophils. Of particular interest, Peak E-stimulated human splenic T cells produced bioactive and immunoreactive IL-5. Marked induction of IL-5 mRNA in Peak E-stimulated T cells was also shown by reverse-transcriptase polymerase chain reaction (RT-PCR). In contrast, L-tryptophan without the contaminant showed none of these effects. Thus, these data suggest that Peak E might be involved in the pathogenesis of EMS through bimodal mechanism including IL-5 generation by T cells and potentiation of eosinophil functional activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132737     DOI: 10.1007/bf01541175

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  36 in total

1.  Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome.

Authors:  W F Owen; J Petersen; D M Sheff; R D Folkerth; R J Anderson; J M Corson; A L Sheffer; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Central-nervous-system effects of ingestin of L-tryptophan by normal subjects.

Authors:  B SMITH; D J PROCKOP
Journal:  N Engl J Med       Date:  1962-12-27       Impact factor: 91.245

3.  L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak.

Authors:  J R Hibbs; B Mittleman; P Hill; T A Medsger
Journal:  Arthritis Rheum       Date:  1992-03

4.  Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan.

Authors:  J S de Oliveira; S B Auerbach; K M Sullivan; G E Sale
Journal:  Bone Marrow Transplant       Date:  1993-02       Impact factor: 5.483

5.  L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.

Authors:  L J Crofford; J I Rader; M C Dalakas; R H Hill; S W Page; L L Needham; L S Brady; M P Heyes; R L Wilder; P W Gold
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

6.  Interleukin 5 activity in sera from patients with eosinophilia.

Authors:  H Enokihara; H Kajitani; S Nagashima; S Tsunogake; N Takano; K Saito; S Furusawa; H Shishido; Y Hitoshi; K Takatsu
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

7.  An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.

Authors:  E A Belongia; C W Hedberg; G J Gleich; K E White; A N Mayeno; D A Loegering; S L Dunnette; P L Pirie; K L MacDonald; M T Osterholm
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

8.  Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.

Authors:  E M Sternberg; M H Van Woert; S N Young; I Magnussen; H Baker; S Gauthier; C K Osterland
Journal:  N Engl J Med       Date:  1980-10-02       Impact factor: 91.245

9.  Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts.

Authors:  W F Owen; M E Rothenberg; D S Silberstein; J C Gasson; R L Stevens; K F Austen; R J Soberman
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

10.  Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3.

Authors:  A F Lopez; L B To; Y C Yang; J R Gamble; M F Shannon; G F Burns; P G Dyson; C A Juttner; S Clark; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

View more
  3 in total

1.  L-tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes.

Authors:  H Barth; R Klein; P A Berg
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.

Authors:  H Takagi; M S Ochoa; L Zhou; T Helfman; H Murata; V Falanga
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 3.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.

Authors:  R E Parchment
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.